As a service to the Society for Immunotherapy of Cancer's (SITC) membership and the oncology community as a whole, SITC offers FREE, CME-certified online education on the topic of immunotherapy through Clinical Advances in Immuno-Oncology, a robust online learning center. Developed through a partnership with Medscape Oncology, this learning center is designed to provide education to oncologists in a variety of immunotherapy related topics beginning with immunology fundamentals and advancing to tumor-specific immunotherapy education. As a new addition, SITC has also partnered with Medscape to offer Patient Education activities for patients, caregivers, or those interested in learning more about specific types of cancer and how immunotherapy can be used for them. To access the patient education activities, please scroll to the bottom of the page!
To access each CME educational activity, click on the topics below. For more online education activities, please visit SITC Cancer Immunotherapy connectED.
Emerging Considerations in the Use of Immune Checkpoint Inhibitors: CRC August 14th, 2017Drs Bendell and Lee discuss the role of checkpoint inhibition in the management of patients with colorectal cancer.Optimizing Outcomes in mRCC: Finding the Balance of Immune InhibitionMay 30, 2017Drs. Atkins and Choueiri discuss the latest advances in the use of immunotherapy in patients with mRCC.State of the Art in HCC: Immune Checkpoint ModulationMarch 24, 2017Listen to 2 experts discuss the latest in immune checkpoint modulation in advanced HCC.
Management of Glioblastoma: Where Have We Been and Where Are We Going?March 23, 2017Leading experts discuss insights on advances in the treatment of glioblastoma.Patient Centered Care in HNSCCFebruary 17, 2017Drs Robert Ferris and Laura Chow discuss some of the practicalities involved in treating patients with HNSCC with checkpoint inhibitors.
Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer December 20, 2016 Experts discuss treatment strategies for one patient with recurrent HNSCC and one with locally advanced HNSCC.
Clinical Challenges in Melanoma: Progressive Disease December 7, 2016 Imaging scans suggest this patient's melanoma has progressed, but has it? Watch this case to see how it develops.
New Frontiers in Decision Making: Adverse Events With Immunotherapy in NSCLC December 6, 2016 Use a patient case to learn about managing adverse events with immunotherapy in patients with NSCLC.Optimizing Outcomes in Metastatic Melanoma: A Case ChallengeNovember 22, 2017Review appropriate treatment regimens for patients with metastatic melanoma
The Nurse View: Overcoming Challenges Associated with Cancer Immunotherapy November 11, 2016 Experts discuss the role of nursing for setting expectations and managing irAEs in patients with melanoma receiving immunotherapy.
New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC October 21, 2016 Follow a patient with advanced squamous cell NSCLC to learn about the use and management of immune checkpoint inhibitors.
Patient-Centered Care in Metastatic Renal Cell Carcinoma September 21, 2016 Explore some of the main issues in the treatment of advanced RCC through 2 cases.
Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer September 14, 2016 Drs Weiss, Borghaei, and Patel discuss the clinical data and practical implications for using checkpoint inhibitors to treat lung cancer.
Pulmonologist Perspectives: How Will the Use of Immune Checkpoint Inhibitors Affect My Practice? August 31, 2016 Learn how treatment of NSCLC with checkpoint inhibitors will affect your clinical outlook.
Cancer Immunotherapy: Pathways and Mechanisms of Actions August 24, 2016 In these 3 columns, experts discuss the basics of the immune system as well as existing and novel targets for cancer immunotherapy.
Checkpoint Inhibitors in First-Line Advanced NSCLC: What Should You Know? August 14th, 2017Learn about monotherapy and combination therapy options for patients eligible for first-line immunotherapy.
March 29, 2017
What are the implications for NSCLC, colorectal cancer, and other tumors?
Dr Jonathan Rosenberg reviews the latest evidence on the use of checkpoint inhibitors in bladder cancer.
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in NSCLC January 18, 2017Learn about the use of checkpoint inhibitors in patients with NSCLC.
Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy December 16, 2016 Watch as an oncologist, pharmacist, and nurse discuss challenges and best practices for working in a team environment.
New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC December 6, 2016 Follow a patient with advanced adenocarcinoma to learn about the use and management of immune checkpoint inhibitorsAdvancing the Care in Thoracic Cancer: Emerging Treatment OptionsNovember 30, 2016Read 3 articles that review immunotherapy treatment options in mesothelioma, small cell lung cancer, and non-small cell lung cancer.
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer November 15, 2016 Dr Tanguy Seiwert explores the emerging role for immunotherapy in head and neck cancer.
Clinical Challenges in Melanoma: Frontline October 21, 2016 A patient undergoing treatment for metastatic melanoma experiences some unusual symptoms. Watch this case to figure out what is going on.
Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma October 14, 2016 Dr Stephen Ansell discusses the emerging role of immunotherapy in the management of patients with Hodgkin lymphoma.
Priming T-Cells: Do We Understand the Strategies? September 15, 2016 Three articles examine the role of T cells in the anticancer immune response and how they are being used in therapy.
Spotlight on Immuno-Oncology in Melanoma August 31, 2016 Drs Weber, Luke, and Gangadhar discuss the latest updates to existing immunotherapies and examine where the future may lie.
Hiding in Plain Sight: How Cancer Evades the Immune System August 24, 2016 Dr Robert Ferris reviews the working of the immune system and the development of cancer.
Additional activities are available in our archive. While these activities are no longer CME-certified, they remain valuable resources for oncologists interested in learning more about cancer immunotherapy.
Is Immunotherapy Right for My Lung Cancer? November 8, 2016 This activity is for people with non-small cell lung cancer who want to learn more about why, how, and when their care team may consider using immunotherapy as part of their treatment.
Immunotherapy Side Effects: Talking With Your Melanoma Care Team November 8, 2016 This article is for people who are taking checkpoint inhibitor medicines for metastatic melanoma, their care partners, and others who want to learn about treatment side effects.
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Regarding lymphatic endothelial cell-related cancer and post-transplant recipients. Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) evades immune killing of tumor cells by relying on its immunomodulatory viral antigens. Organ donors in high seroprevalence ...
There is likely an unpublished cohort of patients throughout the world who were treated with ipilimumab prior to the introduction of nivolumab/ipilimumab combination and achieved an either complete remission or partial remission. These patients then ...
The case report presented here on advanced melanoma, in an elderly patient on page 810, indicates that despite of lack of prior ipilimumab treatment it cannot be excluded that subsequent observed astonishing treatment with nivolumab can partially be due ...
Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy? October 20, 2016 This activity is for people with non-small cell lung cancer (NSCLC) who want to learn more about how immunotherapy differs from chemotherapy.
What Treatment Is Right for My Metastatic Melanoma? October 19, 2016 This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org